Clinical Trials · NCT01796301

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

Name: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Teriparatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Amgen
Enrollment: 436
Start date: Jan 2013
Locations: 50 sites, 11 countries
Primary endpoint: Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)

View Teriparatide compound reference